Guardant Health is proud to partner with biopharma companies, more than 100 to date, to support their efforts in bringing the next generation of cancer therapeutics to patients sooner. Our portfolio of innovative solutions spans translational research – Guardant Explore™, clinical development and commercialization – Guardant Companion™, and real-world evidence – Guardant INFORM™.
Realizing the promise of precision medicine demands a comprehensive, multi-dimensional understanding of a patient’s tumor and immune response. GuardantINFINITY™ provides a unique combined genomic and epigenomic molecular profile revealing unseen insights distinctive to each sample from a single blood draw.
Epigenetic changes occur early in tumorigenesis and are highly pervasive across a tumor type. This allows DNA methylation cancer biomarkers to be suitable for early detection and have utility across a range of areas relevant to cancer detection and treatment. The development of more specific drugs selectively targeting mutated epigenetic modifiers will help restrict effects to tumor cells only and decrease potential side effects.1, 2 GuardantINFINITY detects an aggregated methylation signal that can distinguish cancer patients from cancer-free patients, at 91% sensitivity and 97% specificity across a cohort of lung, breast, and CRC samples (Guardant Health generated data).
Watch our webinar to understand how methylation in liquid biopsy applications can bring novel insights across the continuum of care and accelerate biomarker discovery and patient selection for clinical trials.
800+ gene panel
15MB methylation panel
Epigenic mechanisms can synergize with known driver mutations to facilitate cancer development or evolution.1 GuardantINFINITY provides comprehensive content enabling novel and emerging biomarker identification and helps unravel the complexity of therapeutic response and resistance.
GuardantINFINITY adapts and evolves with your data needs today and beyond. Choose from a range of applications, from measurable/minimal residual disease (MRD) and molecular response to therapy selection from insights on key Immuno-oncology (IO) and homologous repair deficiency (HRD) biomarkers. Select the data you need today with the option to unlock insights from other modules at any time with no burden or delay of an additional sample collection.
Core Module
Gain comprehensive genomic and epigenomic insights uncovering novel tumor profiles to optimize patient selection and a deeper understanding of patient response and resistance, with forward capability to unlock additional insights
Add modules at any time, using the same sample
| Indication | Pan-solid tumor therapy selection, measurable/minimal residual disease (MRD) and longitudinal/response monitoring |
|---|---|
| Genomic Panel | ~4 Mb (>800 genes) |
| Methylation Panel | 15 Mb |
| Sample Requirements | ≥2 mL of plasma (retrospective) 2 x 10 mL of blood (prospective) |
| Report Output | Genotyping (SNV’s, InDel’s, CNA’s, Fusions), tumor mutational burden (TMB), microsatellite instability (MSI), large genomic rearrangements, copy number loss and multi-exon deletion for homologous recombination repair (HRR) genes, sample level methylation detection, tumor fraction score, molecular response and optional add-on modules |
Contact our biopharma team to see how we can help you accelerate precision oncology and bring the next generation of cancer therapies to patients sooner.
Address:
21 Biopolis Road,
# 03-28, Nucleos,
Singapore 138567.
Telephone:
+65 6018 8504
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED